Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Structure Therapeutics Inc. (NASDAQ: GPCR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Structure Therapeutics is incorporated in the Cayman Islands and its American Depositary Shares, each representing three ordinary shares, are registered and listed on the Nasdaq Global Market under the symbol GPCR. The company files reports and current updates with the U.S. Securities and Exchange Commission in connection with its operations and capital markets activities.
Investors reviewing GPCR SEC filings will find current reports on Form 8-K that cover topics such as quarterly financial results, corporate updates, and outcomes of the annual general meeting of shareholders. For example, the company has furnished press releases announcing second and third quarter financial results and business updates via Form 8-K, and has reported shareholder voting results on director elections, auditor ratification, and advisory votes on executive compensation and say-on-frequency matters.
Structure Therapeutics also utilizes an automatic shelf registration statement on Form S-3 to conduct public offerings of American Depositary Shares and pre-funded warrants. Related prospectus supplements and offering documents are filed with the SEC and referenced in the company’s press releases. These filings provide details on the terms of upsized underwritten public offerings, gross proceeds, and the involvement of joint book-running managers and co-managers.
Through this filings page, users can monitor how Structure Therapeutics reports its financial condition, shareholder actions, and significant corporate events in its SEC submissions. Stock Titan enhances access to these documents with tools to quickly locate relevant 8-Ks and registration-related materials and to follow the company’s ongoing reporting history as a Nasdaq-listed clinical-stage biopharmaceutical company focused on oral small molecule GPCR-targeted therapies.
Structure Therapeutics is a clinical-stage biopharma company using structure-based design and computational chemistry to create oral small molecules that target GPCRs for chronic diseases, with a major focus on obesity and metabolic disorders.
The lead candidate, aleniglipron, an oral GLP‑1 receptor agonist, delivered placebo‑adjusted mean weight loss of 11.3% at 120 mg in the 36‑week Phase 2b ACCESS study and 15.3% at 240 mg in the exploratory ACCESS II study, with class‑consistent gastrointestinal side effects and no reported drug‑induced liver injury or QTc issues. Multiple Phase 2 and extension studies support moving into Phase 3 obesity trials in the second half of 2026.
The company is also advancing oral amylin receptor agonists ACCG‑2671 and ACCG‑3535 into Phase 1, plus early GIP and glucagon receptor programs, while retaining a broad GPCR pipeline. In December 2025, a subsidiary licensed certain non‑core GLP‑1 patents to Genentech and Roche for a $100 million upfront payment and future low single‑digit royalties.
Structure Therapeutics Inc. reported its fourth quarter and full-year 2025 results and provided a pipeline update focused on obesity treatments. Positive Phase 2 aleniglipron data showed significant weight loss across all doses, reaching up to 15.3% at 36 weeks, supporting advancement into Phase 3, which is expected to start in the second half of 2026.
The company reported cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, which it expects to fund operations and key clinical milestones through the end of 2028. Fourth quarter 2025 R&D expenses were $68.7 million and full-year R&D totaled $225.3 million, reflecting expanded clinical activity. Other license income of $100.0 million and $10.2 million of gains on sale of non-financial assets contributed to fourth quarter 2025 net income of $33.0 million, compared to a net loss of $36.5 million a year earlier. For full-year 2025, the company recorded a net loss of $141.2 million, compared to a net loss of $122.5 million in 2024.
Structure Therapeutics Inc. received an amended Schedule 13G showing that a group of Biotechnology Value Fund (BVF) entities and Mark N. Lampert collectively report beneficial ownership of 10,437,066 ordinary shares. This equals about 4.9% of the company’s 211,917,574 shares outstanding as of December 11, 2025.
The stake is primarily held through three BVF funds, with BVF owning 5,583,855 shares, BVF II holding 4,053,954 shares and Biotechnology Value Trading Fund OS LP holding 643,536 shares, largely via American Depositary Shares. The filers certify the position is passive and not for influencing control.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 12,335,346 ordinary shares of Structure Therapeutics Inc., equal to 5.95% of the class as of December 31, 2025.
The ownership is calculated using 207,417,574 ordinary shares outstanding as of December 10, 2025, based on the issuer’s prospectus. The position includes 4,111,782 American Depositary Shares, each representing three ordinary shares. The filers certify the holdings are not for the purpose of changing or influencing control of the company.
Structure Therapeutics Inc. received a Schedule 13G/A showing that Wellington Management Group LLP and related entities beneficially own 21,365,952 shares of common stock, representing 10.08% of the company’s outstanding shares as of December 31, 2025.
Wellington reports shared voting power over 19,433,943 shares and shared dispositive power over 21,365,952 shares, with no sole voting or dispositive power. The shares are held of record by Wellington investment-advisory clients, and no single client is said to hold more than five percent of the class.
Wellington certifies the holdings are kept in the ordinary course of business and are not intended to change or influence control of Structure Therapeutics, indicating a passive institutional ownership position.
Structure Therapeutics Inc received an amended Schedule 13G filing showing that FMR LLC and Abigail P. Johnson beneficially own 31,112,634 shares of its common stock, representing 15.0% of the class as of December 31, 2025.
FMR LLC has sole voting and dispositive power over these shares, while Abigail P. Johnson has sole dispositive power. The filers certify that the securities were acquired and are held on a passive basis, not to change or influence control of Structure Therapeutics.
FMR LLC, a 10% owner of Structure Therapeutics Inc. (GPCR), reported several sales of American Depositary Shares on January 15, 2026 through affiliated F-Prime funds. The trades, coded as open-market sales, included transactions such as 465 ADS at $82.10, 330 ADS at $83.35, 552 ADS at $84.22 and 20 ADS at $85.04 for F-Prime Capital Partners Life Sciences Advisors Fund VI LP, and larger blocks like 5,477 ADS at $82.10, 3,880 ADS at $83.35, 6,498 ADS at $84.22 and 230 ADS at $85.04 for F-Prime Capital Partners Life Sciences Fund VI LP.
After these trades, affiliated persons and entities whose holdings are reported by FMR LLC still held 4,546,674 ADS, while the two F-Prime funds held 5,005 ADS and 58,864 ADS, respectively. Each ADS represents three ordinary shares of Structure Therapeutics. The filing notes these positions are reported indirectly and includes a disclaimer that the reporting parties are not admitting beneficial ownership of the securities.
Structure Therapeutics Inc. (GPCR) reported a larger quarterly loss as it advanced multiple clinical programs and strengthened its balance sheet. For the three months ended September 30, 2025, net loss was $65,712 with a basic and diluted loss per share of $0.37, compared with a net loss of $33,977 and $0.20 per share a year ago. Operating expenses rose to $73,787, driven by research and development of $58,989 and general and administrative of $14,798. Interest and other income was $8,183.
The company ended the quarter with $799.0 million in cash, cash equivalents and short‑term investments and estimates this will fund projected operations through at least 2027. In September, it sold 3,040,000 ADSs via its ATM program for gross proceeds of approximately $58.5 million and net proceeds of approximately $55.8 million, leaving about $191.5 million capacity. Development highlights include Phase 2b ACCESS studies of aleniglipron (GLP‑1R agonist) with topline data expected by year‑end 2025, advancement of oral amylin receptor agonists (ACCG‑2671 and ACCG‑3535), completion of a Phase 1 study for LTSE‑2578 (LPA1R antagonist), and an asset sale to Exelixis with $10.0 million in initial payments (with $5.2 million received).
Structure Therapeutics Inc. furnished a current report describing a new press release that provides a corporate update and the company’s financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for those detailed results.
The report clarifies that this information, including Exhibit 99.1, is furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other regulatory documents.
Structure Therapeutics insider transaction: Reporting person Ashley Hall, identified as Chief Development Officer and a director, had 6,021 ordinary shares withheld to satisfy income tax obligations related to the vesting of restricted share units on 09/18/2025. The shares were recorded at a price of $7.7433 per share and reduced Hall's beneficial ownership to 112,317 ordinary shares. The filing notes that the issuer's ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. This appears to be a routine tax-withholding disposition following equity vesting rather than an open-market sale.